Adamas Pharmaceuticals (ADMS) Receives a Hold from Needham

In a report released today, Serge Belanger from Needham maintained a Hold rating on Adamas Pharmaceuticals (ADMS). The company’s shares closed last Wednesday at $4.46.

According to, Belanger is a 4-star analyst with an average return of 5.6% and a 51.0% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Collegium Pharmaceutical.

Currently, the analyst consensus on Adamas Pharmaceuticals is a Strong Buy with an average price target of $8.75.

See today’s analyst top recommended stocks >>

Adamas Pharmaceuticals’ market cap is currently $132.9M and has a P/E ratio of -2.10. The company has a Price to Book ratio of -3.76.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer’s disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts